Author | Phil Febbo, MD | OncLive

Author | Phil Febbo, MD

Articles

Dr. Febbo on the Impact of Oncotype DX Genetic Prostate Score

May 06, 2017

Video

Phil Febbo, MD, chief medical officer, Genomic Health, discusses the impact the Oncotype DX Genetic Prostate Score (GPS) has on patients with clinically low-risk prostate cancer.

Dr. Febbo Explains the Oncotype DX Genomic Prostate Score

March 07, 2017

Video

Phil Febbo, MD, chief medical officer, Genomic Health, explains the Oncotype DX Genomic Prostate Score (GPS) for patients with clinically low-risk prostate cancer.

x